| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PLN; PLB; Cardiac phospholamban; PLB |
| Entrez GeneID | 5350 |
| WB Predicted band size | Calculated MW: 6 kDa; Observed MW: 12,24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human Phospholamban |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Phospholamban(PLN)抗体的参考文献，简要概括其内容：
---
1. **"Phospholamban: A Key Regulator of Cardiac Calcium Homeostasis"**
*Authors: Kranias EG, Hajjar RJ*
摘要：综述了Phospholamban在心脏钙离子调控中的作用，重点讨论了其通过抑制SERCA2a(钙泵)活性影响心肌收缩/舒张的机制，并提及抗体的应用(如Western blot检测PLN表达水平及磷酸化状态)。
2. **"Targeted Ablation of the Phospholamban Gene in Mice Reveals Enhanced Myocardial Function"**
*Authors: Luo W, et al.*
摘要：通过基因敲除技术构建PLN缺陷小鼠模型，利用特异性抗体验证PLN蛋白缺失，发现小鼠心肌细胞钙离子摄取能力增强，提示PLN对SERCA2a的抑制作用及其在心力衰竭中的潜在治疗靶点。
3. **"Differential Effects of Phospholamban and Anti-Phospholamban Antibodies on Ca²⁺-ATPase Activity"**
*Authors: Antipenko AY, et al.*
摘要：研究比较了针对PLN不同磷酸化位点(如Ser16、Thr17)抗体的作用，发现某些抗体可通过模拟PLN磷酸化解除其对SERCA2a的抑制，从而增强钙泵活性，为开发靶向PLN的治疗策略提供依据。
---
以上文献涵盖了PLN抗体的实验应用，包括蛋白表达验证、磷酸化状态分析及功能调控研究，适用于心肌钙信号机制探索及相关疾病模型开发。
Phospholamban (PLN) is a critical regulatory protein in cardiac and skeletal muscle cells, primarily localized to the sarcoplasmic reticulum (SR). It modulates the activity of the SR calcium ATPase (SERCA2a), which is responsible for calcium reuptake during muscle relaxation. In its dephosphorylated state, PLN inhibits SERCA2a, reducing calcium sequestration and slowing relaxation. Upon phosphorylation (e.g., by protein kinase A or Ca²⁺/calmodulin-dependent kinase during β-adrenergic stimulation), this inhibition is relieved, enhancing contractility. Dysregulation of PLN is linked to cardiomyopathies, heart failure, and arrhythmias.
Phospholamban antibodies are essential tools for studying its expression, post-translational modifications, and interactions. These antibodies enable detection of PLN in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific antibodies targeting phosphorylated residues (e.g., Ser16 or Thr17) help assess PLN’s activation status under physiological or pathological conditions, such as ischemia, hypertrophy, or heart failure. Researchers also use PLN antibodies to explore gene therapy approaches (e.g., PLN knockout or inhibition) to restore SERCA2a function in diseased hearts. Their specificity and validation are crucial, as PLN shares structural homology with other proteins. By elucidating PLN’s role in calcium cycling, these antibodies contribute to understanding cardiac pathophysiology and developing targeted therapies.
×
